Post-trial follow-up | Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in early-stage unfavorable Hodgkin Lymphoma

Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial – Journal of Clinical Oncology

Commentaries:

NIVAHL Trial: Nivolumab and AVD Show Favorable Long-Term Safety and Efficacy in Early-Stage Unfavorable Classical Hodgkin Lymphoma – ASCO Daily News

Concomitant and Sequential Nivolumab, Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of German Hodgkin Study Group NIVAHL Trial – The ASCO Post

Original Study: Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial – JAMA Oncology